Insight Pharma Reports RNAi Therapeutics Report

RNAi Therapeutics: Second-Generation Candidates Build Momentum
 
 
InsightPharmaReports.com
InsightPharmaReports.com
 
Spread the Word
Listed Under

Tags:
Rnai
Therapeutics
Mirna
Life Sciences
Biotech
Pharma
Oligo
Report
Phase I
Phase Ii
Rna

Industrys:
Business
Health
Biotech

Location:
Needham - Massachusetts - US

Feb. 23, 2011 - PRLog -- NEEDHAM, MA  -  Insight Pharma Report’s RNAi Therapeutics: Second-Generation Candidates Build Momentum, authored by Allan Haberman, PhD, is now available.

Many established pharma companies have entered into major deals with some of these RNAi therapeutics companies.  Also covered are companies focus on development of microRNA-based therapeutics and diagnostics.  These have attracted the interest of the investment community and the pharmaceutical industry.  This report discusses the outlook for the therapeutic RNAi/miRNA industry sector, including strategic issues such as technological prematurity and the development of enabling technologies, the role of Big Pharma investment, the impact of patent litigation and cross-licensing in shaping the RNAi/miRNA sector, and a scenario for the development of drugs in the therapeutic RNAi/miRNA sector.

Key topics covered include:

                         •   Delivery vehicle technologies
                         •   Oligo protective chemistries
                         •   Therapeutic indications in development
                         •   Phase I and II development highlights
                         •   Big Pharmas’ investments, activities and strategies
                         •   Profiles of leading companies

Following an overview of the discovery and evolution of the RNAi and miRNA field, RNAi Therapeutics: Second-Generation Candidates Build Momentum turns to the science behind therapeutic RNAi and miRNA, technologies for design of therapeutic oligonucleotides that work via an RNAi or miRNA-modulating mechanism, technologies for design of delivery vehicles, and leading companies in the therapeutic RNAi/miRNA industry sector as well as the role of large pharmaceutical companies in the sector.

For more information and to purchase this report, go to:
http://www.insightpharmareports.com/reports_report.aspx?r...

About Insight Pharma Reports (http://www.InsightPharmaReports.com)
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute.  http://www.InsightPharmaReports.com

# # #

Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets.
End
Source:Insight Pharma Reports
Email:***@healthtech.com Email Verified
Phone:781-972-5400
Zip:02494
Tags:Rnai, Therapeutics, Allan Haberman, Mirna, Life Sciences, Biotech, Pharma, Oligo, Report, Phase I, Phase Ii, Rna
Industry:Business, Health, Biotech
Location:Needham - Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Insight Pharm Reports PRs
Trending News
Top Daily News
Top Weekly News



Like PRLog?
9K2K1K
Click to Share